5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

Key Takeaways Explain This Topic AI

Readiness screening for ventilator liberation requires resolution of the acute precipitating cause, PaO2/FiO2 >= 150 to 200 on PEEP <= 5 to 8 cmH2O, hemodynamic stability off or on minimal vasopressors, intact airway reflexes, and an adequate sensorium.

Paired daily Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT)—the ABC trial protocol—significantly shorten duration of mechanical ventilation, reduce ICU stay, and decrease 1-year mortality.

A Rapid Shallow Breathing Index (RSBI = f / Vt in liters) below 105 breaths/min/L measured during unassisted breathing demonstrates high weaning success, whereas an RSBI above 105 strongly predicts extubation failure.

A quantitative cuff leak volume under 110 mL (or under 12% to 24% of delivered tidal volume) predicts high risk for post-extubation laryngeal stridor; administration of intravenous methylprednisolone for 12 to 24 hours prior to extubation significantly reduces stridor and reintubation.

In high-risk extubation patients (age > 65, hypercapnic COPD, congestive heart failure), immediate prophylactic noninvasive ventilation or high-flow nasal cannula reduces post-extubation respiratory failure and reintubation, whereas rescue NIV after unselected post-extubation failure develops increases mortality.

Last updated: October 2026

Liberation from mechanical ventilation is a critical juncture in the management of intensive care patients. Both premature extubation (leading to emergent reintubation, increased aspiration risk, and elevated mortality) and unnecessary delays in extubation (leading to ventilator-associated pneumonia, airway trauma, delirium, and muscle atrophy) significantly worsen patient outcomes. Successful liberation relies on systematic readiness screening, protocolized spontaneous breathing trials, objective airway assessment, and risk-stratified post-extubation support.

1. Readiness Screening Criteria for Liberation

Daily automated or clinician-led screening of mechanically ventilated patients identifies individuals ready to transition toward liberation. Patients must meet four core physiologic criteria:

Resolution or Substantial Improvement of Underlying Disease: Reversal of the primary condition causing acute respiratory failure (e.g., control of septic shock, resolution of pulmonary edema, clearance of acute intoxication).

Adequate Oxygenation and Gas Exchange:

PaO 2 / FiO 2 ≥ 150 – 200 \text{PaO}_2 / \text{FiO}_2 \ge 150\text{--}200 PaO 2 ​ / FiO 2 ​ ≥ 150 – 200 with PEEP ≤ 5 – 8 cmH 2 O \text{PEEP} \le 5\text{--}8\text{ cmH}_2\text{O} PEEP ≤ 5 – 8 cmH 2 ​ O and FiO 2 ≤ 0.40 – 0.50 \text{FiO}_2 \le 0.40\text{--}0.50 FiO 2 ​ ≤ 0.40 – 0.50 .

Arterial pH ≥ 7.25 – 7.30 \text{pH} \ge 7.25\text{--}7.30 pH ≥ 7.25 – 7.30 without severe respiratory acidosis.

Hemodynamic Stability:

Absence of active myocardial ischemia or malignant ventricular arrhythmias.

Adequate mean arterial pressure without vasopressors or on stable, minimal vasopressor support (e.g., norepinephrine ≤ 0.05 mcg/kg/min \le 0.05\text{ mcg/kg/min} ≤ 0.05 mcg/kg/min or vasopressin ≤ 0.03 units/min \le 0.03\text{ units/min} ≤ 0.03 units/min ).

Neurologic & Airway Protective Capacity:

Patient awake, easily arousable, or responsive to verbal commands (RASS − 1 to 0 -1\text{ to }0 − 1 to 0 ).

Intact spontaneous cough during airway suctioning and spontaneous swallowing reflexes.

Absence of ongoing neuromuscular blockade or continuous deep sedative infusions.

2. Paired Awakening and Breathing Protocol (The ABC Trial)

The Awake and Breathing Controlled (ABC) trial (Girard et al., Lancet 2008) established the clinical paradigm of pairing a daily Spontaneous Awakening Trial (SAT) with a Spontaneous Breathing Trial (SBT) . +--------------------------------------------------------+

• | Daily SAT Safety Screening |
• | (No active seizures, no delirium tremens, RASS <= +1) |
• +---------------------------+----------------------------+
• |
• v
• +--------------------------------------------------------+
• | Spontaneous Awakening Trial |
• | (Interrupt all sedatives and opioids) |
• +---------------------------+----------------------------+
• | Pass (Awake/Arousable)
• v
• +--------------------------------------------------------+
• | Daily SBT Safety Screening |
• | (P/F >= 150-200, PEEP <= 8, minimal vasopressors) |
• +---------------------------+----------------------------+
• | Pass
• v
• +--------------------------------------------------------+
• | Spontaneous Breathing Trial |
• | (PS 5-8 cmH2O / PEEP 0-5 cmH2O for 30-120 min) |
• +---------------------------+----------------------------+
• | Pass
• v
• +--------------------------------------------------------+
• | Airway Assessment & Extubation |
• | (Cough strength, secretions, Cuff Leak Test) |
• +--------------------------------------------------------+

Protocol Mechanics: Every morning, continuous sedatives are completely stopped. If the patient passes the SAT (opens eyes to voice, tolerates cessation without sustained agitation or marked tachypnea), they are immediately screened for an SBT.

Evidence-Based Outcomes: Patients managed with paired daily SAT + SBT had more ventilator-free days over 28 days ( 14.7 vs. 11.6 days 14.7\text{ vs. }11.6\text{ days} 14.7 vs. 11.6 days ), shorter ICU and hospital stays, and a 14 % 14\% 14% absolute reduction in 1-year mortality (44% vs. 58%; NNT about 7) compared with SBT plus usual sedation.

SAT Failure Management: If a patient fails the SAT (sustained agitation RASS > + 2 > +2 > + 2 , oxygen desaturation < 88 % < 88\% < 88% , tachypnea > 35 breaths/min > 35\text{ breaths/min} > 35 breaths/min ), sedatives are restarted at half the previous dose , and the patient is re-screened the following morning.

3. Spontaneous Breathing Trial (SBT) Techniques & Parameters

An SBT tests the patient's ability to breathe independently while evaluating cardiovascular reserve.

SBT Delivery Techniques

Low-Level Pressure Support (PSV): The patient breathes with pressure support of 5 – 8 cmH 2 O 5\text{--}8\text{ cmH}_2\text{O} 5 – 8 cmH 2 ​ O and PEEP of 0 – 5 cmH 2 O 0\text{--}5\text{ cmH}_2\text{O} 0 – 5 cmH 2 ​ O . This level of support compensates for the internal resistive drag of the endotracheal tube.

T-Piece Trial: The endotracheal tube is disconnected from the ventilator circuit and connected to an open T-piece adaptor delivering blow-by humidified oxygen. This imposes additional resistive work on the patient.

Note

The ATS/CHEST 2017 Clinical Practice Guideline suggests (conditional recommendation) conducting the initial SBT with inspiratory pressure augmentation ( 5 – 8 cmH 2 O 5\text{--}8\text{ cmH}_2\text{O} 5 – 8 cmH 2 ​ O ) rather than a T-piece or CPAP. Pressure-augmented SBTs had higher SBT success and extubation success, with a nonsignificant trend toward lower ICU mortality and no increase in reintubation; a later trial (Subirà et al., JAMA 2019) found a 30-minute pressure-support SBT produced more successful extubations than a 2-hour T-piece SBT (82.3% vs. 74.0%).

SBT Duration & Failure Criteria

Duration: A 30-minute SBT is non-inferior to a 120-minute trial for low-to-moderate risk patients. High-risk patients with severe COPD, chronic hypercapnia, or marginal cardiac reserve may benefit from extending the SBT to 60 to 120 minutes to uncover latent diaphragmatic fatigue or cardiogenic decompensation.

Objective Failure Criteria:

Respiratory: Respiratory rate > 35 breaths/min > 35\text{ breaths/min} > 35 breaths/min or < 8 breaths/min < 8\text{ breaths/min} < 8 breaths/min ; SpO 2 < 90 % \text{SpO}_2 < 90\% SpO 2 ​ < 90% on FiO 2 ≥ 0.40 \text{FiO}_2 \ge 0.40 FiO 2 ​ ≥ 0.40 ; thoracoabdominal paradox or intercostal muscle retractions.

Cardiovascular: Heart rate > 140 bpm > 140\text{ bpm} > 140 bpm or a > 20 % > 20\% > 20% sustained change from baseline; systolic blood pressure > 180 mmHg > 180\text{ mmHg} > 180 mmHg or < 90 mmHg < 90\text{ mmHg} < 90 mmHg ; new cardiac dysrhythmias or angina.

Neurologic: Agitation, diaphoresis, somnolence, grimacing, or acute encephalopathy.

4. Rapid Shallow Breathing Index (RSBI)

The Rapid Shallow Breathing Index (RSBI) , introduced by Yang and Tobin (NEJM 1991), is the most widely validated bedside physiologic predictor of weaning success.

RSBI = f V t \text{RSBI} = \frac{f}{V_t} RSBI = V t ​ f ​

Where:

f f f is the spontaneous respiratory rate in breaths/min.

V t V_t V t ​ is the spontaneous tidal volume measured in liters (not mL).

Measurement Technique & Diagnostic Accuracy

Protocol: RSBI is accurately measured during 1 minute of completely unassisted spontaneous breathing (PEEP 0, PS 0, or on a T-piece) using a calibrated handheld Wright respirometer or modern ventilator mechanics software.

Diagnostic Thresholds:

RSBI < 105 breaths/min/L \text{RSBI} < 105\text{ breaths/min/L} RSBI < 105 breaths/min/L : High probability of successful weaning and extubation.

RSBI > 105 breaths/min/L \text{RSBI} > 105\text{ breaths/min/L} RSBI > 105 breaths/min/L : High negative predictive value ( > 90 % > 90\% > 90% ), indicating that the patient has inadequate neuromuscular reserve and will almost certainly fail extubation.

Warning

Calculating RSBI while the patient is receiving pressure support ventilation falsely lowers the respiratory rate and elevates tidal volume, artificially suppressing the RSBI value and creating false confidence. Always measure RSBI on zero pressure support to obtain accurate predictive validity.

5. Upper Airway Patency: The Cuff Leak Test

Post-extubation laryngeal edema occurs in 5 % to 15 % 5\%\text{ to }15\% 5% to 15% of critically ill patients following prolonged intubation, resulting in acute post-extubation stridor and life-threatening upper airway obstruction.

Clinical Risk Factors for Laryngeal Edema

Female sex (smaller laryngeal dimensions).

Prolonged mechanical ventilation ( > 6 days > 6\text{ days} > 6 days ).

Large endotracheal tube relative to laryngeal size (e.g., ≥ 8.0 mm \ge 8.0\text{ mm} ≥ 8.0 mm in females).

Traumatic, difficult, or emergency intubation.

High cuff pressures during ICU stay.

The Quantitative Cuff Leak Test

Suction oral secretions thoroughly and suction the trachea above the cuff.

In Volume Control with a known baseline tidal volume ( V t V_t V t ​ ), completely deflate the endotracheal tube cuff.

Measure the average expired tidal volume over the next 6 breaths.

Cuff Leak Volume = Inspired V t V_t V t ​ minus Expired V t V_t V t ​ with cuff deflated.

Cuff Leak Volume = V t , inspired − V t , expired \text{Cuff Leak Volume} = V_{t\text{, inspired}} - V_{t\text{, expired}} Cuff Leak Volume = V t , inspired ​ − V t , expired ​

Thresholds for Abnormal Test (High Stridor Risk):

Absolute cuff leak volume < 110 mL < 110\text{ mL} < 110 mL , OR

Percentage cuff leak < 12 % to 24 % < 12\%\text{ to }24\% < 12% to 24% of the baseline delivered V t V_t V t ​ .

Management of a Failed Cuff Leak Test

If a patient has a failed cuff leak test (leak < 110 mL < 110\text{ mL} < 110 mL ), extubation should be delayed.

Pharmacologic Prophylaxis: Administer intravenous methylprednisolone ( 20 – 40 mg 20\text{--}40\text{ mg} 20 – 40 mg every 4 to 6 hours) or dexamethasone ( 5 mg 5\text{ mg} 5 mg every 6 hours) for 12 to 24 hours 12\text{ to }24\text{ hours} 12 to 24 hours (minimum 4 hours) prior to planned extubation.

Large randomized trials (Cheng et al., Lancet 2006; Francois et al., Lancet 2007) demonstrate that steroid administration for 12 to 24 hours significantly reduces post-extubation laryngeal edema, post-extubation stridor, and reintubation rates.

Extubation should be performed in a controlled setting with video laryngoscopy and an airway exchange catheter immediately available at the bedside.

6. High-Risk Extubation & Post-Extubation Support

Not all patients who pass an SBT have an equal risk of extubation failure. Extubation failure (defined as the need for reintubation within 48 to 72 hours) occurs in 10 % to 20 % 10\%\text{ to }20\% 10% to 20% of unselected ICU patients.

High-Risk Extubation Criteria

Age > 65 years > 65\text{ years} > 65 years .

Underlying chronic cardiopulmonary disease: severe COPD, heart failure with reduced ejection fraction.

Persistent hypercapnia ( PaCO 2 > 45 mmHg \text{PaCO}_2 > 45\text{ mmHg} PaCO 2 ​ > 45 mmHg ) at the completion of the SBT.

Prolonged mechanical ventilation ( > 7 days > 7\text{ days} > 7 days ).

Weak spontaneous cough (peak expiratory cough flow < 60 L/min < 60\text{ L/min} < 60 L/min ) or copious tracheal secretions ( > 2 suctions/hour > 2\text{ suctions/hour} > 2 suctions/hour ).

More than one failed SBT prior to liberation.

Prophylactic Support: Preventive NIV and HFNC

In patients fulfilling high-risk criteria, applying noninvasive respiratory support immediately upon extubation dramatically improves outcomes:

Preventive Noninvasive Ventilation (NIV): Initiated immediately in the operating room or ICU post-extubation for high-risk hypercapnic COPD or heart failure patients. In a randomized trial of hypercapnic patients (Ferrer et al., Lancet 2009), preventive NIV reduced post-extubation respiratory failure (15% vs. 48%) and 90-day mortality.

High-Flow Nasal Cannula (HFNC): Delivers heated, humidified oxygen at rates up to 60 L/min 60\text{ L/min} 60 L/min with low PEEP effect ( 3 – 5 cmH 2 O 3\text{--}5\text{ cmH}_2\text{O} 3 – 5 cmH 2 ​ O ) and dead-space washout. Hernández and colleagues (two JAMA 2016 trials) showed that in low-risk patients HFNC reduced reintubation compared with conventional oxygen (4.9% vs. 12.2%), and in high-risk patients HFNC was noninferior to preventive NIV (reintubation 22.8% vs. 19.1%).

Combined Preventive NIV + HFNC: The HIGH-WEAN trial (Thille et al., JAMA 2019) demonstrated that in high-risk extubated patients, alternating preventive NIV with HFNC between NIV sessions reduced the reintubation rate to 11.8 % 11.8\% 11.8% compared to 18.2 % 18.2\% 18.2% with HFNC alone.

The Lethal Trap of "Rescue" NIV

Caution

While preventive NIV immediately post-extubation saves lives in high-risk patients, applying rescue NIV once an unselected patient has already failed extubation and developed acute respiratory failure is hazardous. The landmark Esteban trial (NEJM 2004) proved that rescue NIV in established post-extubation failure does not reduce reintubation rates, significantly delays necessary reintubation, and was associated with higher ICU mortality (25% with NIV vs. 14% with standard therapy) .

Clinical Rule: If a patient extubated without prophylactic NIV develops acute respiratory failure, perform prompt, controlled reintubation rather than delaying with rescue NIV (unless the failure is unequivocally due to acute cardiogenic pulmonary edema or an isolated hypercapnic COPD exacerbation).